Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF-Reference-Cited by-同舟云学术

Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF

Published:2011-01 Issue:1 Volume:35 Page:87-94
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Smith B. Douglas,Jones Richard J.,Cho Eunpi,Kowalski Jeanne,Karp Judith E.,Gore Steven D.,Vala Milada,Meade Brooke,Baker Sharyn D.,Zhao Ming,Piantadosi Steven,Zhang Zhe,Blumenthal Gideon,Warlick Erica D.,Brodsky Robert A.,Murgo Anthony,Rudek Michelle A.,Matsui William H.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference30 articles.

1. Anti-neoplastic agents. 86. Isolation and structure of bryostatin-1;Pettit;J Am Chem Soc,1982

2. Bryostatin, a non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor;Berkow;Biochem Biophys Res Commun,1985

3. Bryostatins – potent, new mitogens that mimic phorbol ester tumor promoters;Smith;Biochem Biophys Res Commun,1985

4. Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells;Stone;Blood,1988

5. The effects of interleukin-3, bryostatin and thymocytes on erythropoiesis;Sharkis;Ann NY Acad Sci,1989

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Marine derived macrolide bryostatin 4 inhibits the TGF-β signaling pathway against acute erythroleukemia;Cellular Oncology;2024-07-31

2. A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS);Leukemia & Lymphoma;2021-07-21

3. Is more better? An analysis of toxicity and response outcomes from dose-finding clinical trials in cancer;BMC Cancer;2021-07-05

4. Is more better? An analysis of toxicity and response outcomes from dose-finding clinical trials in cancer;2020-08-21

5. Role of Dendritic Cells in Exposing Latent HIV-1 for the Kill;Viruses;2019-12-28